Intravenous line securements and catheterisation are two essential procedures carried out every day in clinical environments. Re-catheterisation due to displacement of lines and catheters leads to lost productivity, compromised care and increasing costs for medical facilities and for public and private sector healthcare providers around the world.
UK-based Silmed was founded to deliver efficiency and effectiveness in healthcare though researching, developing and bringing to market advanced and innovative medical devices for use in disease treatment in clinical environments. The company is currently focused on the Helix Lock product which is a line attachment for securing in place attached medical lines and catheters.
Helix Lock is currently patent-pending but will be released into the market to address the worldwide need for secure line placement. With an estimated global catheter market value of US$32.1 billion by 2016 the introduction of Helix Lock represents a significant commercial opportunity for Thorn Medical.